GlassScriptPhysician profile
Thomas A Freels
NPI 1629524053
$19,640.37
in general payments reported to CMS, 2019-2025
26 companies · $4,097 in 2025
The $4,097 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,936 · 2022: $3,767 · 2023: $5,822 · 2024: $4,019 · 2025: $4,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,710 · Travel and Lodging: $5,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,710.46 |
| Travel and Lodging | $5,227.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $4,576.49 | 2023-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $4,439.23 | 2021-2024 | Proclaim, Eterna |
| Medtronic, INC. | $3,258.54 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $2,043.24 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, Superion Indirect Decompression System |
| Spinal Simplicity, LLC | $1,172.89 | 2023 | Ha Minuteman G3-R |
| Curonix LLC | $1,064.02 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.63 | 2021-2025 | Relistor |
| Vertos Medical, INC. | $441.25 | 2023-2024 | Mild Device Kit |
| Stimwave Technologies Incorporated | $417.46 | 2021-2022 | |
| Nevro Corp. | $313.00 | 2021-2022 | |
| Si-Bone, INC. | $224.97 | 2024-2025 | |
| Grt US Holding, INC. | $213.83 | 2021-2022 | |
| Merz North America, INC. | $145.37 | 2022-2025 | |
| Mml US, INC. | $140.85 | 2023 | Reactiv8 |
| Collegium Pharmaceutical, INC. | $128.76 | 2021-2024 | Belbuca, Xtampza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $126.22 | 2021-2024 | Ztlido |
| Galderma Laboratories, L.P. | $108.97 | 2021-2025 | |
| Abbvie INC. | $73.49 | 2025 | |
| Arbor Pharmaceuticals, INC. | $47.15 | 2021 | |
| Averitas Pharma INC. | $46.28 | 2024 | Qutenza |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Hikma Pharmaceuticals USA | $41.72 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $18.66 | 2023 | Horizant |
| Pfizer INC. | $16.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.32 | 2023 | Quviviq |
| Eisai INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Freels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.